These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

571 related articles for article (PubMed ID: 26501146)

  • 1. Neovascular Age-Related Macular Degeneration.
    Shao J; Choudhary MM; Schachat AP
    Dev Ophthalmol; 2016; 55():125-36. PubMed ID: 26501146
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Management of Neovascular Age-related Macular Degeneration: A Review on Landmark Randomized Controlled Trials.
    Agarwal A; Aggarwal K; Gupta V
    Middle East Afr J Ophthalmol; 2016; 23(1):27-37. PubMed ID: 26957836
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vitreomacular Interface after Anti-Vascular Endothelial Growth Factor Injections in Neovascular Age-Related Macular Degeneration.
    Veloso CE; Kanadani TM; Pereira FB; Nehemy MB
    Ophthalmology; 2015 Aug; 122(8):1569-72. PubMed ID: 26038338
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Aflibercept therapy for exudative age-related macular degeneration resistant to bevacizumab and ranibizumab.
    Bakall B; Folk JC; Boldt HC; Sohn EH; Stone EM; Russell SR; Mahajan VB
    Am J Ophthalmol; 2013 Jul; 156(1):15-22.e1. PubMed ID: 23706500
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Wet age related macular degeneration management and follow-up.
    Alexandru MR; Alexandra NM
    Rom J Ophthalmol; 2016; 60(1):9-13. PubMed ID: 27220225
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-Utility Analysis of VEGF Inhibitors for Treating Neovascular Age-Related Macular Degeneration.
    Brown GC; Brown MM; Rapuano S; Boyer D
    Am J Ophthalmol; 2020 Oct; 218():225-241. PubMed ID: 32565050
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Aflibercept administration in neovascular age-related macular degeneration refractory to previous anti-vascular endothelial growth factor drugs: a critical review and new possible approaches to move forward.
    Lazzeri S; Ripandelli G; Sartini MS; Parravano M; Varano M; Nardi M; Di Desidero T; Orlandi P; Bocci G
    Angiogenesis; 2015 Oct; 18(4):397-432. PubMed ID: 26346237
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Initial improvements when converting eyes with treatment-resistant exudative AMD to aflibercept are substantially diminished after increasing treatment intervals from 4 to 8 weeks.
    Jørstad ØK; Faber RT; Moe MC
    Acta Ophthalmol; 2015 Sep; 93(6):e510-1. PubMed ID: 25708506
    [No Abstract]   [Full Text] [Related]  

  • 9. Systemic levels of vascular endothelial growth factor before and after intravitreal injection of aflibercept or ranibizumab in patients with age-related macular degeneration: a randomised, prospective trial.
    Zehetner C; Kralinger MT; Modi YS; Waltl I; Ulmer H; Kirchmair R; Bechrakis NE; Kieselbach GF
    Acta Ophthalmol; 2015 Mar; 93(2):e154-9. PubMed ID: 25488124
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Switch to Aflibercept in the Treatment of Neovascular AMD: One-Year Results in Clinical Practice.
    Pinheiro-Costa J; Costa JM; Beato JN; Freitas-da-Costa P; Brandão E; Falcão MS; Falcão-Reis F; Carneiro ÂM
    Ophthalmologica; 2015; 233(3-4):155-61. PubMed ID: 25896317
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration.
    Heier JS; Brown DM; Chong V; Korobelnik JF; Kaiser PK; Nguyen QD; Kirchhof B; Ho A; Ogura Y; Yancopoulos GD; Stahl N; Vitti R; Berliner AJ; Soo Y; Anderesi M; Groetzbach G; Sommerauer B; Sandbrink R; Simader C; Schmidt-Erfurth U;
    Ophthalmology; 2012 Dec; 119(12):2537-48. PubMed ID: 23084240
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ranibizumab and aflibercept for the treatment of wet age-related macular degeneration.
    Yazdi MH; Faramarzi MA; Nikfar S; Falavarjani KG; Abdollahi M
    Expert Opin Biol Ther; 2015; 15(9):1349-58. PubMed ID: 26076760
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The role of Aflibercept in the management of age-related macular degeneration.
    Hassan M; Afridi R; Sadiq MA; Soliman MK; Agarwal A; Sepah YJ; Do DV; Nguyen QD
    Expert Opin Biol Ther; 2016; 16(5):699-709. PubMed ID: 26982640
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and Efficacy of Anti-Vascular Endothelial Growth Factor Therapies for Neovascular Age-Related Macular Degeneration: A Report by the American Academy of Ophthalmology.
    Bakri SJ; Thorne JE; Ho AC; Ehlers JP; Schoenberger SD; Yeh S; Kim SJ
    Ophthalmology; 2019 Jan; 126(1):55-63. PubMed ID: 30077616
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Advances in pharmacotherapy for wet age-related macular degeneration.
    Santarelli M; Diplotti L; Samassa F; Veritti D; Kuppermann BD; Lanzetta P
    Expert Opin Pharmacother; 2015; 16(12):1769-81. PubMed ID: 26165696
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Aflibercept: A review of its effect on the treatment of exudative age-related macular degeneration.
    Papadopoulos Z
    Eur J Ophthalmol; 2019 Jul; 29(4):368-378. PubMed ID: 30813810
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neovascular age-related macular degeneration.
    Veritti D; Sarao V; Lanzetta P
    Ophthalmologica; 2012; 227 Suppl 1():11-20. PubMed ID: 22517121
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Severe Ocular Inflammation Following Ranibizumab or Aflibercept Injections for Age-Related Macular Degeneration: A Retrospective Claims Database Analysis.
    Souied EH; Dugel PU; Ferreira A; Hashmonay R; Lu J; Kelly SP
    Ophthalmic Epidemiol; 2016; 23(2):71-9. PubMed ID: 26855278
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An efficacy analysis of anti-vascular endothelial growth factor therapy for choroidal neovascularization secondary to multifocal choroiditis and comparison with wet age-related macular degeneration.
    Feng L; Hu JH; Chen J; Xie X
    J Zhejiang Univ Sci B; 2018 Apr.; 19(4):327-332. PubMed ID: 29616508
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Interest of optical coherence tomography performed immediately before intravitreal injection of anti-VEGF in exudative AMD].
    Moyal L; Cohen SY; Pedinielli A; Semoun O; Lalloum F; Jung C; Souied E
    J Fr Ophtalmol; 2015 Sep; 38(7):573-9. PubMed ID: 25997681
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.